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Diabetes mellitus is the most common chronic disease in the world, and a wide range of drugs, including Chinese herbs, have
been evaluated for the treatment of associated metabolic disorders. This study investigated the potential hypoglycemic and
renoprotective eﬀects of an extract from the solid-state fermented mycelium of Cordyceps sinensis (CS). We employed the KK/HIJ
diabetic mouse model, in which the mice were provided with a high-fat diet for 8 weeks to induce hyperglycemia, followed
by the administration of CS or rosiglitazone for 4 consecutive weeks. Several parameters were evaluated, including changes in
body weight, plasma lipid proﬁles, oral glucose tolerance tests, insulin tolerance tests, and plasma insulin concentrations. Our
results show that the CS extract signiﬁcantly elevated HDL/LDL ratios at 4 weeks and decreased body weight gain at 8 weeks.
Interestingly, CS treatment did not lead to obvious improvements in hyperglycemia or resistance to insulin, while in vitro MTT
assays indicated that CS protects pancreatic beta cells against the toxic eﬀects of STZ. CS also enhanced renal NKA activity and
reduced the accumulation of mesangial matrix and collagen deposition. In conclusion, CS extract can potentially preserve β-cell
function and oﬀer renoprotection, which may aﬀord a promising therapy for DM.
1.Introduction
Diabetes mellitus (DM) is the most common chronic disease
in the world, and the number of diabetic patients is rapid-
ly increasing each year. Diabetes-related complications im-
pose a huge healthcare burden [1, 2]. Approximately 90%
of diabetic patients have type 2 DM, in which insulin
resistance plays a central role. Type 2 DM can induce insulin
resistance syndrome, which is associated with obesity, hyper-
lipidemia, hypertension, atherosclerotic heart disease, and
other systemic diseases [3, 4]. Developing new therapeutic
strategies for hyperglycemia and insulin resistance in these
diabetic patients is thus an important issue in public health
worldwide.
Animal models play a major role in research related to
diabetes. Appropriate animal models are essential tools for
the study of type 2 DM pathogenesis, its complications, the
genetic and environmental inﬂuences that increase its risk,
and the development of therapeutic agents [5–7]. Several
types of gene knock-out mice have been developed as animal
models for type 2 DM in recent years [8–10]. The KK/HIJ
mousemodelisawell-establishedanimalmodelfordiabetes.2 Evidence-Based Complementary and Alternative Medicine
In this study, we fed KK/HIJ mice a high-fat diet (HFD) for 8
weekstoinducehyperglycemia.Wethenstudiedtheeﬀectsof
extracts from Cordyceps sinensis in this KK/HIJ mouse model
of diabetes.
Cordyceps sinensis (CS), also called Dong Chong Xia Cao
(winter worm summer grass) in Chinese, is one of the most
valued herbs in traditional Chinese medicine [11–15]. In
previous studies, CS has been proven to have signiﬁcant
hypoglycemic activity in genetic and streptozotocin-induced
diabetic mice and rats [16, 17]. Recent reports also indicate
that the fermented mycelia of CS have anti-hyperglycemic
activities similar to those of CS fruiting bodies in rats with
induced type 1 diabetes [18].
Diabetic nephropathy (DN) is one of the major forms of
chronic kidney disease (CKD). It is a common and serious
complication of diabetes mellitus, leading to renal failure in
up to 30% of individuals with diabetes; DN has thus become
one of the most important end-stage renal diseases (ESRD).
A nongenetic model of type 2 DM has been described that
involves feeding with a high fat diet and administering a
low dose of STZ, resulting in insulin-resistance and hyper-
lipidemia in mice and rats [14]. One clinical study has
demonstrated that renal function in patients with chronic
allograft nephropathy (CAN) signiﬁcantly improved after 6
months of treatment with CS [19]. One in vitro study also
indicated that CS can reduce angiotension-2-induced renal
tubular epithelial cell apoptosis [20].
Despite these reports, there is still little information
regarding the eﬀects of CS on the pancreas and kidneys in
animal models of type 2 DM. We therefore designed this in
vivo pharmacological study to determine the eﬀects of CS on
blood glucose, cholesterol triglycerides, HDL/LDL, glucose
tolerance,andinsulintoleranceindiabeticKK/HIJmice.The
aim of this study was to investigate the potential eﬀects of
fermented CS mycelium extract on diabetes, including pan-
creaticβ-cellpreservationandprotectionofkidney function.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Culture medium RPMI-1640,
fetal bovine serum, sodium bicarbonate, L-glutamine, and
0.05% trypsin-EDTA were purchased from Life Technolo-
gies (Carlsbad, CA., USA). Streptozotocin (STZ), sulforho-
damine B sodium salt (SRB), and rosiglitazone (RS) were
from Sigma (Saint Louis, Missouri, USA). Mouse mono-
clonal antibodies-PPARγ and HRP anti-mouse IgG were
from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
Nitrocellulose membranes were purchased from NEN Life
Science Products (Boston, MA, USA). Mouse insulin and
glucose ELISA kits were from Mercodia (Sylveniusgatan,
Uppsala, Sweden).
2.2. Preparation of Cordyceps sinensis Crude Extract. Com-
mercial pulverized crude extract from the solid-state fer-
mented mycelium of Cordyceps sinensis (CS) used in this
study was provided by Blue Ocean Universal Bio-Tec Co.,
Ltd.(Taipei,Taiwan).TheCSwasextractedwith95%alcohol
by stirring overnight at room temperature; after ﬁltering,
the residues were extracted twice with 95% alcohol using
the above procedure. The CS extract was then concentrated
anddehydratedbyfreeze-drying(Kingmech,FD20L-6S,Tai-
wan). The extraction rate was 25.6%. The solid-state (solid)
fermented CS extract contained no fruiting bodies, and a
dose of 300mg/kg/day equals approximately 300mg/kg/day
of CS mycelia.
2.3. Animal Preparation. Six-week-old male KK/HIJ mice
were purchased from the Jackson Laboratory (Biolasco,
Taiwan). All animals were maintained in laminar ﬂow
cabinets under speciﬁc pathogen-free conditions in facilities
approved by the Accreditation of Laboratory Animal Care
and in accordance with the Institutional Animal Care and
UseCommittee(IACUC)oftheAnimalResearchCommittee
in the Chi-Mei Medical Center, Tainan, Taiwan. The cages,
bedding, food, and water were autoclaved. Animals were
maintained on a daily 12hr light/12hr dark cycle. The
KK/HIJ mouse is an obese diabetic model in which the Ay
mutation is introduced into aKK strainbackground. To sim-
ulatetype2DM,KK/HIJmicewerefedahigh-fatdiet(HFD)
consisting of 40% (wt/wt) fat for 8 consecutive weeks, while
other KK/HIJ mice were given normal chow as a control. CS
(300mg/kg/day) and RS (0.5mg/kg/day) were administered
orally to diabetic KK/HIJ mice for 2 or 4 consecutive weeks.
During experiments, the body weight was recorded regu-
larly and blood samples were drawn from the retro-orbital
sinus of animals weekly for monitoring of the nonfasting
plasma glucose levels (2hr postprandial hyperglycemia). All
enrolled mice, in groups of 16, were weighed at 0, 2, and 4
weeks. After sacriﬁcing 8 mice per group for examination,
the body weight of the remaining 8 mice was recorded at 8
and 12 weeks.
2.4. Determination of Biochemical Indexes. After 2 or 4 weeks
of being fed a high-fat diet, treatments with CS and RS
were begun in diabetic KK/HIJ mice. Blood samples were
prepared and centrifuged, and blood glucose levels were
analyzed using MAJOR II (Taipei, Taiwan); insulin was
measuredusinganinsulinELISAkit(MercodiaAB,Sweden).
Serum levels of total plasma cholesterol (TC), high-density-
lipoprotein cholesterol (HDL-C), low-density-lipoprotein
cholesterol (LDL-C), and triglycerides (TG) were analyzed
using a blood chemistry analyzer (Hitachi 7040).
2.5. Oral Glucose Tolerance Test (OGTT). After an overnight
fast, 3g/kg D-glucose was administered orally to KK/HIJ
mice (normal diet), and the mice (HFD) treated daily with
CS, RS, and control, respectively, for 4 consecutive weeks.
To measure the fasting blood glucose levels, the blood
samples were collected from each subject at 0, 15, 45, 95,
and 135 minutes relative to the start of the oral glucose
administration. The KK/HIJ mice (normal diet) served as
native controls in comparison to the KK/HIJ mice (HFD),
treated with CS, RS, or saline.
2.6. Insulin Tolerance Test. After fasting overnight, 0.5U
insulin was administered intraperitoneally to all mice dailyEvidence-Based Complementary and Alternative Medicine 3
for 4 consecutive weeks. To measure fasting blood glucose
levels, blood samples were collected from each subject at 0,
15,45,95,and135minutesrelativetothestartoftheoralglu-
cose administration. The KK/HIJ mice (normal diet) served
as native controls in comparison to the KK/HIJ mice (HFD).
2.7. In Vitro Cell Culture. Rat insulinoma cells (RIN-m5F)
were purchased from the American Type Culture Collection
and maintained in RPMI-1640 medium supplemented with
10% fetal bovine serum, 2mM L-glutamine, 1.5g/L sodium
bicarbonate, 4.5g/L glucose, 10mM HEPES, and 1.0mM
sodium pyruvate. For experiments, cells were subcultured
into T75 Flask Equivalents; the medium was changed every
2d a y s .
2.8. Cell Toxicity Assessment. The viability of rat pancreatic
insulinoma cells (RIN-m5F) was measured by the reduc-
tion of MTT [3-(4,5-dimethylthiazol-2-yle) 2,5-mdiphenyl-
tetralozium bromide]. Cells were harvested when in the
exponential growth phase, then cultured in 100μLo ff r e s h
medium at 5 × 104 cells/well in 96-well plates. Cells
were incubated in 5% CO2 at 37◦C. After 24 hours, the
suspensions were removed and coincubated with CS extracts
and STZ for 48 and 72 hours, respectively.
Cell proliferation was then assayed using the MTT assay
as follows. PBS solution (20μL) containing 5mg/mL MTT
was added to each well; cells were further incubated for 4
hours then solubilized in 100μLD M S Of o ro p t i c a ld e n s i t y
measurements at 570nm. Cell proliferation was expressed as
the ratio of the number of MTT-treated cells to the number
of control cells (% of control).
2.9. Western Blotting Analysis. At the end of the experi-
ment, all mice were sacriﬁced and their livers prepared for
the analysis of expression of proteins relevant to insulin
resistance. The tissues were ground, centrifuged, and incu-
bated in protein extraction buﬀer for 1 hour. Samples
were centrifuged at 14 000rpm for 30min. Proteins were
separated by 10% PAGE, then transferred onto nitrocellulose
membranes.Afterblocking,membraneswereincubatedwith
anti-PPAR-γ antibody (1:200) for 1 hour at room tempera-
ture in rinse buﬀer, followed by four washes of 10 minutes
each. Horseradish peroxidase-conjugated anti-rabbit IgG
and anti-mouse IgG antibodies were diluted 1:5000 in
rinse buﬀer and incubated with blots for 1 hour at room
temperature. Horseradish peroxidase was added (Reagent A
+ Reagent B, 1:1 ratio) to visualize antibody-bound PPARγ
protein on the NC membrane. Western blot images were
obtained using a LAS-3000 analyzer (Fuji, Japan).
2.10. Na+/K+-ATPase Activity Assay. Membrane ATPase
activity was assayed. The method used allowed the distinct
quantiﬁcation of Na+/K+-ATPase and Mg2+-ATPase activ-
ities as a result of extracting all proteins from the renal
cortex. The enzymatic activities were measured in triplicate
incovered96-wellmicrotiterplatesat 37±0.5◦Conashaker.
Thirty microliters of assay buﬀer (118mM NaCl, 1.67mM
KCl, 1.2mM MgCl2, 12.3mM NaHCO3, 11mM glucose,
0.5mM EGTA, 3mM ATP, and 1.25mM ouabain, pH 7.4)
was added to each well. The plates were read on an ELISA
microplatereaderat630nm.Theabsorbancevaluesobtained
were converted to activity values by linear regression using
a standard curve for sodium monobasic phosphate that was
included in the assay kit. The Na+/K+-ATPase activity was
determined by subtracting the ouabain-insensitive (Mg2+-
ATPase) activity from the overall Na+/K+/Mg2+-ATPase
activity level. Values reported represent the mean and SE of
at least three separate experiments.
2.11. The Masson Trichrome Staining. Kidney samples were
ﬁxedin10%formal-salinefor48hours,andthendehydrated
by successively passing through a gradient of mixtures of
ethyl alcohol and water. The samples were rinsed with xylene
and embedded in paraﬃn. Kidney sections (5μm thick)
were prepared and stained with biebrich scarlet-acid fuchsin
solution for 15 minutes, then transferred directly to aniline
blue solution and stained for 5–10 minutes. Finally, the
sections were mounted using neutral deparaﬃnated xylene
(DPX) medium for microscopic examination on a Motic BA
400 microscope using Motic Advance 3.0 software.
2.12. Statistical Analysis. Values represent mean ± SE with 8
mice per group. Diﬀerences between groups were analyzed
with an analysis of variance (ANOVA) followed by one-way
ANOVA and analyzed using Sigma Plot 10.0 software (SPSS
Inc., Chicago, IL, USA). Each value is expressed as the means
± SE of 8 mice. ∗represented P<0.05, signiﬁcantly diﬀerent
compared with native control of KK/HIJ mice. #represented
P<0.05, compared with the samples separated for 48 hours.
3. Results
3.1. The HDL/LDL Ratio, Cholesterol, Triglyceride, and Body
Weight. Consecutive administration of 300mg/kg/day of
Cordyceps sinensis (CS) for 4 weeks had no obvious eﬀect
on cholesterol (Figure 1(a)) and triglyceride (Figure 1(b))
levels compared to normal controls (normal diet) or the
control group (HFD), while 0.5mg/kg/day of rosiglitazone
(RS) treatment reduced triglyceride levels at 2 and 4 weeks
in KK/HIJ mice. However, CS and RS treatments both
signiﬁcantly elevated the HDL/LDL ratio compared to the
control group (HFD) at 4 weeks (Figure 1(c)). During weeks
4–8, mice were not administered CS or RS, but their body
weight began to increase in the CS and control groups. The
data also showed a much slower body weight gain in the RS
group, with this trend continuing through the end of the 12-
week observation period (Figure 1(d)).
3.2. Glucose Tolerance Test. Glucose intolerance in mice fed
a HFD was more severe than in mice fed a normal diet
(Figure 2(a)). After 2 weeks of treatment with CS or RS,
sequential blood glucose levels declined only in the RS group
(Figure 2(b)). For 4 consecutive weeks, mice in the RS
group progressively increased in their sensitivity to glucose;
meanwhilethediﬀerenceinglucosetolerancebetweentheCS








































































































































Figure 1: The blood biochemical index (cholesterol, triglyceride, and HDL/LDL ratio) and body weight of KK/HIJ mice. Blood samples
were collected from the retroorbital sinus and the cholesterol (a), triglyceride, (b) and HDL/LDL (c) levels were measured following
administration of 300mg/kg/day of Cordyceps sinensis (CS), 0.5mg/kg/day of rosiglitazone (RS), or saline (control group) for 4 consecutive
weeks in HFD-treated KK/HIJ mice. Blood chemistry was analyzed on weeks 2 and 4 using a blood analyzer (Hitachi 7040). The body weight
gain was recorded at 0, 2, 4, 8, and 12 weeks (d). Data are mean ± SE (n = 8 for each group); ∗P<0.05, as compared to the control group.
period, being at 0, 15, 45, 95 and 135min (Figure 2(c)).
Accordingly, at 4 weeks, the nonfasting results indicate that
the total glucose levels were signiﬁcantly decreased by RS but
not by CS (Figure 2(d)).
3.3. Insulin Tolerance Test. Figure 3(a) shows the changes
in blood glucose levels after an insulin injection in native
KK/HIJ mice (normal diet) and the control group (HFD)
on day 0. The HFD control group showed elevations in
f a s t i n gb l o o dg l u c o s el e v e l so v e rt h a to fm i c ef e dan o r m a l
diet at all time points tested after insulin administration.
Results indicate that, after 2 weeks of treatment, neither CS
nor RS signiﬁcantly decreased fasting blood glucose levels
(Figure 3(b)). After 4 weeks of treatment, mice treated with
RS were less insulin tolerant at the later time points (45–180
minutes) compared to mice in the control and CS groups
(Figure 3(c)). After 4 weeks of drug administration, plasma
nonfasting insulin levels were increased in CS group mice
and decreased in RS group mice compared with that of
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Figure 2: Eﬀects of Cordyceps sinensis extract on oral glucose tolerance test. After 8 weeks of being fed a high-fat diet, KK/HIJ mice were
treated with 300mg/kg/day of CS extract and 0.5mg/kg/day of rosiglitazone (RS) for 4 consecutive weeks and were compared to native
controls(normaldiet)andcontrolgroup(HFD)after0(a),2(b),and4(c)weeks.Afteranovernightfast,3g/kgD-glucosewasadministered
orally.Bloodsampleswereobtainedforevaluationofglucoselevelsat0,15,45,95,and135min.Nonfastingglucosevalues(2hrpostprandial
hyperglycemia) (d) were also determined 4 weeks later using a glucometer on blood samples. Data are mean ± SE (n = 8 for each group);
∗P<0.05, as compared to the control group.
3.4. CS Protection of Pancreatic Beta Cells against STZ Cyto-
toxicity. The viability of mouse pancreas insulinoma beta
cells (RIN-m5F) was used to determine whether CS confers
protection against STZ toxicity. Incubation of beta cells with
STZ alone resulted in a decrease in cell viability to 56%
and 32% of controls after 48 and 72hrs of incubation,
respectively (Figure 4). When co-treated with STZ and CS,
beta cells demonstrated a marked increase in cell survival
over those treated with STZ alone.
3.5. PPAR-γ Protein Expression. I no r d e rt oe l u c i d a t et h e
insulin-sensitizingeﬀectsofRSandCS,weemployedwestern
blot analysis and found that mice treated with RS had
dramaticallyincreasedlevelsofexpressionofPPAR-γ protein
in liver tissues. However, the administration of CS did not
eﬀectively increase PPAR-γ protein levels over that of the
control group (Figure 5).
3.6.Na+/K+-ATPaseActivity. Enzymeactivityassaysrevealed
that Na+/K+-ATPase activity in the renal cortex was signif-
icantly elevated after 4 weeks of CS treatment compared to
that of control and RS groups (Figure 6).
3.7. Kidney MT Staining. We examined mouse renal cortical























































































Figure 3: Eﬀect of Cordyceps sinensis extract on insulin tolerance test (ITT). After 8 weeks of being fed a high-fat diet, KK/HIJ mice were
treated with 300mg/kg/day of CS extract and 0.5mg/kg/day of rosiglitazone (RS) for 4 consecutive weeks and were compared to native
controls (normal diet) and control group (HFD) after 0 (a), 2 (b), and 4 (c) weeks. After an overnight fast, 0.5U insulin was administered
intraperitoneally. The blood samples were obtained to determine glucose concentrations at 0, 15, 45, 95, and 135min. Nonfasting serum
insulin levels (d) were determined using an insulin ELISA kit 4 weeks later. Data are expressed as mean ± SE (n = 8 for each group);
∗P<0.05, as compared to the control group.
verity of overt nephropathy as indicated by collagen ﬁbril
deposition in glomeruli, tubules, and the interstitium. As
shown in Figure 7, the renal cortex of native KK/HIJ mice
who were fed a normal diet showed positive collagen
staining within glomeruli (which remain relatively intact)
but weak collagen staining in the tubules and interstitium
(Figure 7(a)). After 4 weeks of being fed a high-fat diet, glo-
merular mesangial matrix accumulation and strong collagen
staining in glomeruli, tubules, and interstitium were appar-
entintissuesfromthecontrolgroup(HFD)(Figure7(b)).In
samples from mice treated with CS, the degree of mesangial
matrix accumulation and collagen staining in diﬀerent renal
compartments seemed much improved over that of the
control group (Figure 7(c)). However, samples from mice
treated with RS showed no obvious improvement in collagen
deposition and mesangial matrix accumulation compared to
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Figure 4: The viability of pancreatic beta cells (RIN-m5F) in vit-
ro. The viability of beta cells (RIN-m5F) was measured after 48
or 72 hours of incubation with either STZ (2mM), CS extract
(10μg/mL), or combined combination of STZ (2mM) with CS ex-
tract (10μg/mL). Each value represents the mean ± SE of three
replicate experiments and expressed as population growth. ∗P<
0.05 diﬀered from saline control. #P<0.05 diﬀered signiﬁcantly
















































Figure 5: PPAR-γ protein expression in liver tissue. Expression
levels of the PPAR-γ and β-actin proteins were determined by
western blot and quantitated by microcomputer image device
(MCID) image analysis. After 8 weeks of being fed a high-fat diet,
KK/HIJ mice were treated with 300mg/kg/day of CS extract and
0.5mg/kg/day of rosiglitazone (RS) for 4 consecutive weeks and
were compared to the control group (HFD). The PPAR-γ protein
expressionlevelswereevaluatedinliver(comparedtoβ-actin)atthe
end of the test period. Data are expressed as the mean ± SE (n = 8
for each group); ∗P<0.05, as compared to the control group.








































































Figure 6: Renal Na+/K+-ATPase activity. Na+/K+-ATPase activity
in the renal cortex of KK/HIJ mice (HFD) after treatment with
300mg/kg/day of Cordyceps sinensis (CS) and 0.5mg/kg/day of ro-
siglitazone (RS) for consecutive 4 weeks as compared to native con-
trols(normaldiet)andthecontrolgroup(HFD).Dataareexpressed
as mean ± SE (n = 8 for each group); ∗P<0.05, as com- pared to
the control group.
4. Discussion
The hypoglycemic activity of CS in genetic and experimen-
tally induced diabetic mouse models has been previously
described [13, 14, 16, 17]. After daily oral, intravenous,
or intraperitoneal administration of CS extract for several
weeks, signiﬁcant reductions in fasting blood glucose levels,
attenuation of polydipsia, and improvements in glucose tol-
erance have been observed in several streptozotocin-induced
and genetic diabetic animal models. Some CS extract pro-
ductswerealsoproven to increase insulin sensitivity [21,22].
The main active ingredients of CS have been shown to
be polysaccharides, major components of fungal structures.
Despite this evidence, information regarding the inﬂuence
of CS extracts on pancreatic β cells and renal tissue in
type 2 DM animal models is still lacking. Our study dem-
onstrated that ethanol extracts of CS had no obvious hypo-
glycemic activity and no ability to induce insulin sensitiza-
tion. However, we found that CS confers signiﬁcant pro-
tective eﬀects in several tissues in our type 2 DM mouse
model, potentially reducing DM-related complications such
as diabetic nephropathy and β-cell destruction.
Similar to the ﬁndings of previous animal studies, our
in vivo study showed increased blood insulin levels in these
mice treated with CS, which may be due to the stimulation
of pancreatic β cells [17, 22]. In addition, mice treated with
CS had less body weight gain and better glucose tolerance
than did controls, although these data were not statistically
signiﬁcance. Our results diﬀer from those of previous stud-
ies in several ways. Initially, serum total cholesterol and
triglyceride levels in our KK/HIJ diabetic mice had no ob-
vious improvement after CS administration; but the HDL/
LDL ratio increased after 4 weeks, implying that CS was ca-
pable of improving lipid proﬁles. On the other hand, insulin













Figure 7: Histopathological examination of the renal cortex using Masson’s trichrome staining. Histopathological study of the renal cortex
in native KK/HIJ and HFD-fed KK/HIJ mice after treatment with either 300mg/kg/day Cordyceps sinensis (CS), 0.5mg/kg/day rosiglitazone
(RS), or the control group (saline) for 4 consecutive weeks. (a) In the native control group, the glomerulus (white arrow) remained relatively
intact with positive collagen staining; weak collagen staining was present in tubules and the interstitium. (b) In KK/HIJ (HFD) mice treated
with saline, obvious mesangial matrix accumulation with diﬀuse collagen ﬁbril deposition in diﬀerent compartments was observed. (c) In
KK/HIJ mice treated with CS, the matrix accumulation and collage staining was less severe than that in controls. (d) In KK/HIJ mice treated
with RS, obvious mesangial matrix accumulation and diﬀuse collagen staining within renal tissues were observed (Masson trichrome, 400x).
expression levels of hepatic PPAR-γ protein, which has been
shown to correlate well with insulin sensitivity in several
animal models [23–25]. One possible reason for the lack
of eﬀect could be that the ethanol extract from CS might
contain several other non-polysaccharide components that
could play an important role in inducing the previously
observed hypoglycemic eﬀects. In addition, the KK/HIJ
mouse strain has potentially severe insulin resistance, which
may make the degree of improvement diﬃcult to evaluate
while using lower doses of CS extract [26–28].
Interestingly, although no obvious improvement in
insulin sensitivity was noted after CS extract use, in vitro
cytoxicityassaysdemonstratedthatpancreaticβ-cellviability
increased dramatically with CS extract treatment, implying
that CS protects β cells. From a clinical perspective, preserva-
tion of β-cell function and survival should be taken into con-
siderationwhenchoosingmedicationsforDM[29].Sulfony-
lureas, which are often used as the ﬁrst line of defense in dia-
betes therapy, had been found to accelerate β-cell exhaustion
and apoptosis [30]. In some diabetic animal studies, certain
drugs have demonstrated the ability to rescue or rejuvenate
beta cells; such drugs include an ATP-sensitive K+ channel
opener (diazoxide) [31], the thiazolidinediones (TZDs) [32],
and newly developed incretin mimetics and enhancers [33].
Therefore,thepotentialabilityofCSextracttopreservebeta-
cell function may aﬀord a promising therapy for DM. This is
an important ﬁnding from our in vitro studies.
Diabetic nephropathy is the leading cause of end-stage
renal disease, aﬀecting more than 40% of diabetic patients
worldwide. It is also one of the most signiﬁcant long-
term complications in morbidity and mortality for diabetic
patients [34]. Therefore, studies of the pathophysiology and
mechanisms of diabetic nephropathy are very important.
Renal Na+/K+ ATPase (NKA), a major transporter of renal
sodium, may play a role in diabetic nephropathy. In one
study of STZ-induced diabetes in rats, NKA activity was
found to be decreased by 40% in erythrocytes, sciatic nerves,
and kidneys [35]. NKA activity is also decreased in the
medullary thick ascending limb in of STZ-induced diabetic
rats 12 weeks after induction [36]. The activity of renal NKA
was found to be downregulated in animal models of chronic
hyperglycemia, and advanced glycation end products mayEvidence-Based Complementary and Alternative Medicine 9
play an important role in this process [37]. Due to the diﬃ-
cultyofaccessingrenaltissueinhumanstudies,NKAactivity
has usually been measured via erythrocytes. Several studies
have shown decreased erythrocyte NKA activity in diabetic
patients [38, 39]. However, the eﬀects on preservation of
N K Aa r en o to b s e r v e dw h i l et r e a t e dw i t hR S .T h e r e f o r e ,
decreasedNKAactivityisthoughttobeapotentialriskfactor
forthedevelopmentofdiabeticnephropathyinbothanimals
and humans, especially while the disease is in progression
[40]. In our study, NKA activity signiﬁcantly increased
after the use of CS extract for several weeks. Whether the
CS extract has a renoprotective eﬀect still remains to be
determined by further investigations.
Our study had several limitations. First, some of our
results have a trend suggesting that CS extract leads to im-
provements in biochemical laboratory parameters, but with-
out signiﬁcance. More signiﬁcant impacts might be “mask-
ed” due to severe insulin resistance in KK/HIJ mice. Despite
this limitation, no previous studies have investigated the
glucose-lowering eﬀects of solid-state fermented Cordyceps
sinensis to this extent. Second, the duration of CS extract
administration may be short (4 weeks). Nevertheless, the
eﬀects of CS on pancreatic beta cell preservation, increased
renalNKAactivity,andreducedrenalcollagendepositionare
still signiﬁcant.
In conclusion, this preliminary study suggests that CS
extractpromotesβ-cellsurvival,increasesrenalNKAactivity,
and decreases collagen deposition and mesangial matrix ac-
cumulation. These beneﬁcial actions indicate that CS might
be a potential drug candidate for retardation of pancreatic
β-cell failure and diabetic nephropathy. In future studies, we
plan to use diﬀerent diabetic mouse models with less insulin
resistance than KK/HIJ mice and increase the duration of CS
extract administration.
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